[ad_1]
<! –
->
<! –
->
More than 200 million cases of malaria were recorded in Africa in 2017 according to the World Health Organization (WHO), which set itself the goal of reducing the incidence of malaria and the rates World mortality rate of at least 90% by 2030.
In order to reach this goal, scientists from seven institutions in sub-Saharan Africa, coordinated by the Kumasi Collaborative Center for Tropical Medicine, have launched a 48-month long clinical research on triple therapy for treatment of malaria in African children.
ArteSunate + Amodiaquine + Atovaquone-Proguanil Tritherapy (ASAAP) for the treatment of malaria in African children.
It is hoped that ASAAP will develop one of the first fixed-dose antimalarial tritherapies to slow antimalarial drug resistance, as well as the risk of mosquito transmission from one person to another by mosquitoes.
Over the next four years, ASAAP will use its network to develop a platform for clinical trials, entomology and molecular biology in Benin, Ghana, Mali, Gabon and Burkina Faso.
Malaria is preventable and curable. Its control currently rests on three main tools: long-lasting insecticide-treated mosquito nets to prevent mosquito bites, rapid and accurate diagnostic tests to identify parasite carriers, and effective, safe and well-tolerated antimalarials to prevent infection and cure the disease.
With these tools and the increase in international funding over the past two decades, it is estimated that the prevalence of parasitic infection of malaria and the incidence of clinical illness have decreased by 50 % and 40% in sub-Saharan Africa between 2000 and 2015.
However, the malaria burden has remained stable since 2016. In 2017, most cases of malaria were in the WHO African Region (200 million or 92%).
Ten countries in sub-Saharan Africa – including Burkina Faso, Ghana, and India – and India support nearly 80% of the global malaria burden.
WHO Global Technical Strategy for Malaria Control
The WHO has set ambitious targets for the 2016-2030 period, including a reduction of at least 90% in global malaria mortality and incidence rates by 2030.
The strategy calls for further research and development of new malaria control tools for its elimination.
Currently, the tools available to control malaria are under enormous pressure because of the resistance of the malaria parasite to drugs.
The ASAAP project is part of the 2/3 EDCTP2 program supported by the Director of Research and Development of the European Union for the Ghana Health Service, Dr. Abraham Hodgson, said the best approach was to find several ways to treat the disease.
According to him, despite continued malaria vaccination, the search for alternative drugs will accelerate efforts to achieve WHO's goal.
[ad_2]
Source link
